Abstract 653P
Background
EBC-129 is a humanised IgG1 linked to monomethyl auristatin E (MMAE) via the clinically validated MC-vc-PAB linker. It targets a conformational epitope specific for N256-glycosylated CEACAM5 & CEACAM6 (N256 C5/C6) which is highly tumour specific. This study evaluates safety and preliminary efficacy of EBC-129 in advanced solid tumors.
Methods
The multicentre Phase 1A dose escalation study used a Bayesian design to establish the recommended Phase 2 dose (RP2D) of EBC-129. Patients (pts) failing standard therapies, with adequate organ function and ECOG 0-1 were eligible and received doses between 0.3 and 2.2 mg/kg every 3 weeks, until disease progression. The primary endpoint is safety; secondary endpoints include efficacy and PK. Prospective central assessment of archival tissue to determine IHC positivity (≥20% at 2+ or 3+) was performed in ≥30% of pts (NCT05701527) using a validated assay.
Results
As of 24 Apr 2024, 16 pts received ≥1 dose of EBC-129. Most pts were male (75%) and Asian (63%), with a median (range) age of 59 (53-76) and 3 (1-9) lines of prior therapy. The RP2D is 2.2 mg/kg, the MTD was not reached and back-filling at lower doses is ongoing. One DLT was observed at 2.2 mg/kg (G4 febrile neutropenia). The most common TRAEs were Gr 1-2 infusion-related reactions. Transient Gr 3/4 neutropenia occurred in 5 pts (at 1.8 and 2.2 mg/kg). Treatment-related neuropathy was not seen. Of 14 evaluable pts, there were 2 PRs (oesophageal and pancreatic adenocarcinoma at 1.2 mg/kg and 1.8 mg/kg respectively), 7 pts are currently ongoing. IHC positivity for N256 C5/6 in archival tissues was most frequent in colorectal (94%), followed by gastric (64%), pancreatic (57%), oesophageal and lung cancers (53% each).
Conclusions
EBC-129 is the first ADC to target N256C5/6 and has shown promising early activity in a heavily pre-treated population. Additional targeting of C6 did not increase toxicity seen with MMAE-linked ADCs. Three expansion cohorts (n=15 each) in IHC positive gastroesophageal or other cancers, and in pancreatic cancer (IHC positive or ≥ 1% expression at 3+) are ongoing.
Clinical trial identification
NCT05701527.
Editorial acknowledgement
Legal entity responsible for the study
Experimental Drug Development Centre (EDDC), A∗STAR.
Funding
National Research Foundation (NRF), Singapore.
Disclosure
M.C.H. Ng: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, BeiGene, BMS, Merck, MSD, Novartis, Pfizer; Financial Interests, Institutional, Financially compensated role: Amgen, BMS, Eli Lilly, MSD, Taiho; Non-Financial Interests, Personal, Non financial benefits, travel support: AstraZeneca, BMS; Non-Financial Interests, Personal, Non financial benefits, travel support: MSD; Financial Interests, Personal, Stocks/Shares: AstraZeneca. F. Meric-Bernstam: Financial Interests, Personal, Other, Consultant: AstraZeneca, OnCusp Therapeutics, Zymeworks; Financial Interests, Personal, Other, Consulting: Calibr, Ecor1, Exelixis, GT Aperion, Infinity Pharmaceuticals, Loxo Oncology, LegoChem Bio, Lengo Therapeutics, Tallac Therapeutics, Becton Dickinson, eFfector Therapeutics, Jazz Pharmaceuticals; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Incyte, Karyopharm, Protai, TheraTechnologies, Zentalis, FogPharma, Harbinger Health, Mersana Therapeutics, Sanofi Pharmaceuticals; Financial Interests, Personal, Other, Consulting: Menarini Group; Financial Interests, Personal, Advisory Board/Consultant: Seagen; Financial Interests, Personal, Invited Speaker: Dava Oncology; Financial Interests, Institutional, Other, Local PI / Research Grant: Aileron Therapeutics, Bayer Healthcare, CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., eFfector Therapeutics, Taiho Pharmaceutical Co.; Financial Interests, Institutional, Other, Local PI / Research Grant / Coordinating PI: AstraZeneca; Financial Interests, Institutional, Local PI: Calithera Biosciences, Curis Inc., Debiopharm International, Guardant Health Inc., Klus Pharma, Novartis, Jazz Pharmaceuticals, Zymeworks; Financial Interests, Institutional, Other, Local PI / Steering Committee Member: Genentech Inc.; Financial Interests, Institutional, Research Grant: Takeda Pharmaceutical Co., Puma Biotechnology Inc., Repare; Other, Travel support: European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO); Other, Travel Support: Cholangiocarcinoma Foundation, Dava Oncology. R.W. Lentz: Financial Interests, Institutional, Research Funding: ALX Oncology, Merck, Eli Lilly, Guardant, EDDC; Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim, Agenus. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01